Haven't got a glue: Protein surface variation for the design of molecular glue degraders.
Sign Up to like & getrecommendations! Published in 2021 at "Cell chemical biology"
DOI: 10.1016/j.chembiol.2021.04.009
Abstract: Molecular glue degraders are small, drug-like compounds that induce interactions between an E3 ubiquitin ligase and a target, which result in ubiquitination and subsequent degradation of the recruited protein. In recent years, serendipitous discoveries revealed… read more here.
Keywords: molecular glue; glue degraders; protein surface;
Abstract A026: Discovery of potent and selective CDK2 molecule glue degraders for the treatment of HR+/HER2- breast cancer, and CCNE1 amplified tumors
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a026
Abstract: The Cyclin-Dependent Kinase 2 (CDK2) is a key oncology target and promotes cell cycle progression by binding to its cyclin binding partners, especially, Cyclin E (CCNE1). The activated CCNE1/CDK2 complex phosphorylates RB and promotes cellular… read more here.
Keywords: glue degraders; cancer; cdk2; breast ... See more keywords
Abstract C132: Screening of Molecular Glue Degraders Using the DIANTHUS Technology Platform
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-c132
Abstract: Molecular glues represent a promising therapeutic modality by inducing targeted protein-protein interactions (PPIs) to modulate disease-relevant pathways. The DIANTHUS technology platform (Spectral shift, TRIC) enables the rational design and discovery of molecular glues through a… read more here.
Keywords: technology; glue degraders; screening molecular; technology platform ... See more keywords
Abstract 3424: Template-assisted covalent modification of DCAF16 enables BRD4 molecular glue degraders
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3424
Abstract: Molecular glue degraders have emerged as a powerful class of small-molecule therapeutics, as demonstrated by the clinical successes of thalidomide analogs in the treatment of hematological malignancies. These small molecules act by recruiting ubiquitin ligases… read more here.
Keywords: dcaf16; glue degraders; covalent modification; molecular glue ... See more keywords